Guillain-Barré syndrome: Difference between revisions

From IDWiki
(Created page with "== Etiology == * ''Campylobacter jejuni'' * Cytomegalovirus * Epstein-Barr virus * Zika virus * HIV * Non-infectious causes, including imunization, surgery...")
 
No edit summary
Line 1: Line 1:
== Etiology ==
== Background ==

* ''[[Campylobacter jejuni]]''
* Causes either acute inflammatory demyelinating polyneuropathy, or acute motor axonal neuropathy, or acute motor and sensory axonal neuropathy
* [[Cytomegalovirus]]

* [[Epstein-Barr virus]]
===Etiology===
* [[Zika virus]]

* [[HIV]]
*''[[Campylobacter jejuni]]''
* Non-infectious causes, including imunization, surgery, trauma, and hematopoietic stem cell transplantation
*[[Cytomegalovirus]]
*[[Epstein-Barr virus]]
*[[Zika virus]]
*[[HIV]]
*Non-infectious causes, including immunization, surgery, trauma, and hematopoietic stem cell transplantation

=== Epidemiology ===

* About 1 case per 100,000 people per year in Western countries

== Clinical Manifestations ==

* Ascending paralysis ± sensory involvement
* Usually occurs 1 to 2 weeks after an immune-stimulating even such as illness or vaccination
** Preceding illness usually a gastrointestinal or respiratory infection
** [[Campylobacter jejuni]] is the most common causative organism identified
** Rare following influenza vaccination; most notable was the 1976 H1N1 vaccine, with about 1 in 100,000 vaccine recipients developing GBS

== Further Reading ==

* Guillain-Barré syndrome. ''Lancet''. 2016;388:717-727. doi: [https://doi.org/10.1016/S0140-6736(16)00339-1 10.1016/S0140-6736(16)00339-1]

[[Category:Neurology]]
[[Category:Infectious diseases]]

Revision as of 01:42, 14 July 2020

Background

  • Causes either acute inflammatory demyelinating polyneuropathy, or acute motor axonal neuropathy, or acute motor and sensory axonal neuropathy

Etiology

Epidemiology

  • About 1 case per 100,000 people per year in Western countries

Clinical Manifestations

  • Ascending paralysis ± sensory involvement
  • Usually occurs 1 to 2 weeks after an immune-stimulating even such as illness or vaccination
    • Preceding illness usually a gastrointestinal or respiratory infection
    • Campylobacter jejuni is the most common causative organism identified
    • Rare following influenza vaccination; most notable was the 1976 H1N1 vaccine, with about 1 in 100,000 vaccine recipients developing GBS

Further Reading

References

  1. ^  Helle Al-Hakem, Alex Y. Doets, Amro Maher Stino, Sasha A. Zivkovic, Henning Andersen, Hugh J. Willison, David R. Cornblath, Kenneth C. Gorson, Zhahirul Islam, Quazi Deen Mohammad, Søren Hein Sindrup, Susumu Kusunoki, Amy Davidson, Carlos Casasnovas, Kathleen Bateman, James A.L. Miller, Bianca van den Berg, Christine Verboon, Joyce Roodbol, Sonja E. Leonhard, Samuel Arends, Linda W.G. Luijten, Luana Benedetti, Satoshi Kuwabara, Peter Van den Bergh, Soledad Monges, Girolama A. Marfia, Nortina Shahrizaila, Giuliana Galassi, Yann Pereon, Jan Bürmann, Krista Kuitwaard, Ruud P. Kleyweg, Cintia Marchesoni, María J. Sedano Tous, Luis Querol, Lorena Martín-Aguilar, Yuzhong Wang, Eduardo Nobile-Orazio, Simon Rinaldi, Angelo Schenone, Julio Pardo, Frederique H. Vermeij, Waqar Waheed, Helmar C. Lehmann, Volkan Granit, Beth Stein, Guido Cavaletti, Gerardo Gutiérrez-Gutiérrez, Fabio A. Barroso, Leo H. Visser, Hans D. Katzberg, Efthimios Dardiotis, Shahram Attarian, Anneke J. van der Kooi, Filip Eftimov, Paul W. Wirtz, Johnny P.A. Samijn, H. Jacobus Gilhuis, Robert D.M. Hadden, James K.L. Holt, Kazim A. Sheikh, Noah Kolb, Summer Karafiath, Michal Vytopil, Giovanni Antonini, Thomas E. Feasby, Catharina Faber, Hans Kramers, Mark Busby, Rhys C. Roberts, Nicholas J. Silvestri, Raffaella Fazio, Gert W. van Dijk, Marcel P.J. Garssen, Jan Verschuuren, Thomas Harbo, Bart C. Jacobs, R.A.C. Hughes, H.P. Hartung, L.C. de Koning, M. Mandarakas, M. van Woerkom, R.C. Reisin, S.W. Reddel, S.T. Hsieh, J.M. Addington, S. Ajroud-Driss, L. Alessandro, U.A. Badrising, G. Balloy, I.R. Bella, T.E. Bertorini, R. Bhavaraju-Sanka, M. Bianco, T.H. Brannagan, K. Brennan, C. Briani, S. Butterworth, C.C. Chao, S. Chen, K.G. Claeys, M.E. Conti, J.S. Cosgrove, M.C. Dalakas, M. Derejko, M.M. Dimachkie, A. Echaniz-Laguna, C. Fokke, T. Fujioka, E.A. Fulgenzi, T. García Sobrino, C.J. Gijsbers, J.M. Gilchrist, J.M. Goldstein, J. Goodfellow, N.A. Goyal, S. Grisanti, L. Gutmann, M. Htut, K. Jellema, I. Jericó Pascual, M.C. Jimeno-Montero, K. Kaida, H. Kerkhoff, M. Khoshnoodi, L. Kiers, M. Kuwahara, J.Y. Kwan, S.S. Ladha, L. Landschoff Lassen, V. Lawson, E. Lee Pan, M.P.T. Lunn, H. Manji, C. Márquez Infante, E. Martinez Hernandez, G. Mataluni, M.G. Mattiazzi, C.J. McDermott, G.D. Meekins, G. Morís de la Tassa, C. Nascimbene, R.J. Nowak, P. Orizaola, M. Osei-Bonsu, A. Pardal, E. Pascual-Goñi, R.M. Pascuzzi, V. Prada, M. Pulley, I. Rojas-Marcos, S.A. Rudnicki, G.M. Sachs, L. Santoro, A. Savransky, L. Schwindling, Y. Sekiguchi, C.L. Sommer, C-Y Tan, H. Tankisi, P.T. Twydell, P. van Damme, T. van der Ree, R. van Koningsveld, J.D. Varrato, V. Vélez Santamaria, C. Walgaard, Y. Yamagishi, L. Zhang, MM, L. Zhou. CSF Findings in Relation to Clinical Characteristics, Subtype, and Disease Course in Patients With Guillain-Barré Syndrome. Neurology. 2023;100(23). doi:10.1212/wnl.0000000000207282.